UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Mark One)

ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended February 28, 2010

o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ______ to _____

Commission File No. 001-32526

BSD Medical Corporation (Exact Name of Registrant as Specified in Its Charter)

Delaware (State or other jurisdiction of incorporation or organization) 75-1590407 (I.R.S. Employer Identification No.)

2188 West 2200 South Salt Lake City, Utah 84119 (Address of principal executive offices, including zip code)

(801) 972-5555 (Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \circ No o

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: BSD MEDICAL CORP - Form 10-Q

Large accelerated filer o Non-accelerated filer o Accelerated filer o Smaller reporting company ý

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý

As of April 13, 2010, there were 23,215,772 shares of the Registrant's common stock, \$0.001 par value per share, outstanding.

BSD MEDICAL CORPORATION FORM 10-Q

FOR THE QUARTER ENDED FEBRUARY 28, 2010

PART I - Financial Information

Item 1. Financial Statements (Unaudited)

Condensed Balance Sheets	3
Condensed Statements of Operations	4
Condensed Statements of Cash Flows	5
Notes to Condensed Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial	
Condition and Results of Operations	14
Item 3. Quantitative and Qualitative Disclosures About Market Risk	30
Item 4. Controls and Procedures	30
PART II - Other Information	
Item 1A. Risk Factors	31
Item 5. Other Information	31
Item 6. Exhibits	32
Signatures	33

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

BSD MEDICAL CORPORATION Condensed Balance Sheets (Unaudited)

ASSETS	February 28, 2010	August 31, 2009
Current assets:		
Cash and cash equivalents	\$5,854,697	\$7,791,938
Accounts receivable, net of allowance for doubtful accounts of \$20,000	493,394	289,617
Related party trade accounts receivable	12,436	41,016
Income tax receivable	1,417,006	1,415,758
Inventories, net	2,047,128	1,794,476
Other current assets	98,507	94,536
Total current assets	9,923,168	11,427,341
Property and equipment, net	1,331,643	1,352,384
Patents, net	66,693	77,633
	\$11,321,504	\$12,857,358

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:		
Accounts payable	\$325,229	\$226,905
Accrued liabilities	388,420	548,079
Deferred revenue – current portion	73,266	67,851
Total current liabilities	786,915	842,835
Deferred revenue – net of current portion	132,030	73,534
Total liabilities	918,945	916,369

Commitments and contingencies

Stockholders' equity:		
Preferred stock, \$.001 par value; 10,000,000 shares authorized, no shares issued		
and outstanding	-	-
Common stock; \$.001 par value, 40,000,000 shares authorized, 23,215,772 and		
22,039,301 shares issued, respectively	23,216	22,040
Additional paid-in capital	30,920,417	28,593,305
Treasury stock, 24,331 shares at cost	(234)	(234)
Accumulated deficit	(20,540,840)	(16,674,122)
Total stockholders' equity	10,402,559	11,940,989
	\$11,321,504	\$12,857,358

Edgar Filing: BSD MEDICAL CORP - Form 10-Q

See accompanying notes to condensed financial statements

BSD MEDICAL CORPORATION Condensed Statements of Operations (Unaudited)

	Three Months Ended February 28,		Six Months Ended February 28,	
	2010	2009	2010	2009
Revenues:				
Sales	\$586,448	\$627,701	\$859,343	\$1,836,097
Sales to related parties	13,626	102,328	166,934	125,496
Total revenues	600,074	730,029	1,026,277	1,961,593
Operating costs and expenses:				
Cost of sales	517,079	388,630	743,599	989,110